Abstract: Long-term survivors of Hodgkin's lymphoma are at increased risk for a number of late complications, including development of second malignancies and cardiovascular disease. Treatment-related factors and other modifying risk factors contributing to the risk of late effects have been identified. Survivors deemed at increased risk based on their treatment history and other exposures may benefit from early detection for late complications and risk reduction strategies. However, the optimal screening tests and prevention program, and their timing and frequency are not clear. It should be noted that treatment for Hodgkin's lymphoma has undergone considerable changes over the last several decades. Most of the current data on late effects after Hodgkin's lymphoma are based on patients treated with outdated chemotherapy and radiation therapy. As Hodgkin's lymphoma therapy evolve over time, continued documentation of late effects associated with newer treatment will be important for the follow-up of patients treated in the modern era.
L ong-term survivors of Hodgkin's lymphoma are at significantly increased risk for a number of late complications, some of which are known to contribute to their excess mortality over time. Several studies have shown that although the cumulative incidence of mortality from Hodgkin's lymphoma plateaus over time, mortality from other causes continues to rise with increasing follow-up time, with second malignancy and cardiac disease being the 2 leading causes of death in these patients. [1] [2] [3] A clear understanding of the various late effects of treatment, their timing and associated risk factors can facilitate the development of optimal follow-up plan for long-term survivors, including screening and prevention strategies. Furthermore, recognition of therapy-related complications can guide treatment modification in newly diagnosed patients to minimize future late effects.
SECOND MALIGNANCY
Since the early 1970s, there has been an accumulation of literature characterizing second malignancies after Hodgkin's lymphoma. Traditionally, second malignancy after Hodgkin's lymphoma had been divided into 3 main categories: leukemia, nonHodgkin's lymphoma, and solid tumors.
Leukemia
The increased risk of leukemia was first described in the early 1970s in patients who had been treated for Hodgkin's lymphoma. 4 The risk seemed to be the highest in the first 10 years after treatment.
The risk was largely related to the use of alkylating chemotherapy in a dose-related manner. 5, 6 Although splenectomy and the addition of large-field radiation therapy to chemotherapy have been postulated as additional risk factors, data are conflicting. 6, 7 The prognosis of leukemia after Hodgkin's lymphoma is extremely poor, with a median survival of less than 1 year. 3 With the replacement of mechlorethemine, vincristine, procarbazine, and prednisone (MOPP) by adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), the risk of leukemia has been substantially reduced. In a recent large, international population-based study by Schonfeld et al, 8 a significant reduction in absolute excess risk of acute myeloid leukemia was found in patients who were treated for Hodgkin's lymphoma after 1985, which is likely explained by changes in chemotherapy over time. However, alkylators are still used in the setting of salvage treatment and are included in some of the modern regimens including bleomycin, etoposide, doxorubicin, cyclophosphamide, procarbazine, and prednisone (BEACOPP) and Stanford V. 9, 10 The risk of secondary leukemia may therefore remain even in patients treated in the modern era.
Non-Hodgkin's Lymphoma
An increased risk of non-Hodgkin's lymphoma after Hodgkin's lymphoma has also been observed. 3, 11, 12 Its timing and relationship with prior therapy, however, is unclear. Development of non-Hodgkin's lymphoma after Hodgkin's lymphoma may be treatment induced. It could also be part of the natural course of Hodgkin's lymphoma, especially for the lymphocyte predominant subtype, or it may be related to the immunosuppressed status of Hodgkin's lymphoma patients. In a study from the German Hodgkin's Study Group, patients who developed non-Hodgkin's lymphoma within 3 months after completion of Hodgkin's lymphoma therapy had a significantly worse prognosis than patients who developed non-Hodgkin's lymphoma beyond 12 months (2-year OS, 20% versus 42%). 13 Age-adjusted International Prognostic Score also significantly predicted for treatment outcome.
Solid Tumors
As the number of survivors of Hodgkin's lymphoma increases and with longer follow-up time, solid tumors had emerged as the major subtype of second malignancy, accounting for up to 75% to 80% of all cases of second malignancy. 3, 11, 12, 14, 15 Solid tumors typically develop after a long latency of at least 10 years after the initial Hodgkin's lymphoma treatment. In addition, the risk seems to persist as long as beyond 30 years after the initial diagnosis. The most common solid tumors observed in long-term survivors of Hodgkin's lymphoma include breast, lung, and gastrointestinal malignancies. 3,14 -16 Two case-control studies had examined in detail the relationship between radiation dose and the risk of breast cancer after Hodgkin's lymphoma therapy. 16, 17 In the study by van Leeuwen et al, 17 the breast cancer risk was significantly increased only after a radiation dose of 38.5 Gy or higher but not at lower doses. In a larger, international case-control study by Travis et al, 16 a radiation dose of Ͼ4 Gy to the breast was associated with a 3.2-fold breast cancer risk compared with women who received lower doses of radiation and no alkylating chemotherapy. The risk increased to eightfold for women who received Ͼ40 Gy to the breast (P trend Ͻ 0.001).
A significant radiation dose-response relationship has similarly been shown for the development of lung cancer after Hodgkin's lymphoma. In a case-control study by Travis et al, 18 the increased risk of lung was statistically significant only after exposure to doses of 30 Gy or higher, compared with patients who received Ͻ5 Gy to the area of the lung in which cancer developed.
Limited data are available on solid tumor risk after chemotherapy alone. In a British cohort study, which included 1693 patients treated with chemotherapy (largely alkylating chemotherapy) alone, the relative risk of lung cancer after chemotherapy alone was found to be significantly increased at 3.3 compared with the matched-general population. 12 A subsequent case-control study from the same group, 19 and another study by Travis et al, 18 both showed a significant dose-response relationship between cumulative doses of alkylating chemotherapy and lung cancer risk.
Other factors also influence the risk of treatment-related solid tumors after Hodgkin's lymphoma. Young age at mantle irradiation has been consistently shown to be associated with significantly increased risk of breast cancer in women. 3, 11, 15 Hormonal exposures also seem to play an important role in the development of breast cancer after Hodgkin's lymphoma. Treatment exposure to alkylating chemotherapy and pelvic irradiation with resulting premature menopause had been found to be protective against breast cancer. 16, 17 Another well-documented risk factor is tobacco exposure on lung cancer development. In a case-control study by Travis et al, 18 a multiplicative effect of tobacco history on the risk of treatmentrelated lung cancer was shown. In patients who had received chest irradiation and alkylating chemotherapy, and had a tobacco history, the lung cancer risk was 49-fold higher than patients who had none of the exposures.
CARDIOVASCULAR DISEASE
The relative risks of cardiac mortality in survivors of Hodgkin's lymphoma have been estimated to range from 2.2 to 7 and the absolute excess risk range from 9.3 to 28/10,000 personyears. 2,3,20 -22 A wide spectrum of cardiac complications have been reported in long-term survivors of Hodgkin's lymphoma. [23] [24] [25] [26] [27] These include pericardial disease, valvular disease, conduction abnormalities, ventricular dysfunction, and coronary disease.
Cardiovascular Disease After Mediastinal Irradiation
The relationship between mediastinal irradiation for Hodgkin's lymphoma and long-term risk of fatal cardiovascular complications is well documented. 1, 28, 29 In addition, the risk seems to be dose related, as demonstrated in the study by Hancock et al, 20 in which cardiac mortality was significantly increased in patients who received more than 30 Gy to the mediastinum, but the increase was not significant in patients who received 30 Gy or less.
In addition to cardiac mortality, data on cardiac morbidity after Hodgkin's lymphoma therapy are also available. In a retrospective study from the University of Florida on 415 patients with history of Hodgkin's lymphoma, 30 10 .4% of patients developed coronary artery disease at a median follow-up of 9 years posttreatment. On multivariable analysis, the only treatment-related risk factor significantly associated with risk of coronary artery disease was the use of a matched mantle and paraaortic field when compared with mantle alone or subdiaphragmatic treatment alone. Aleman et al 31 from the Netherlands reviewed 1474 survivors of Hodgkin's lymphoma younger than 41 years at treatment. At a median follow-up of 18.7 years, the relative risks of myocardial infarction and congestive heart failure were significantly increased at 3.6 and 4.9, respectively. The relative risk of myocardial infarction became significantly elevated after 10 years, and it remained significantly elevated for at least 25 years after treatment. On multivariable analysis, mediastinal radiotherapy was associated with significantly increased risks of valvular disorders, coronary heart disease, and congestive heart failure. Several studies have also shown that traditional cardiac risk factors, including hypertension, hypercholesterolemia, and smoking significantly contribute to the subsequent risk of cardiac disease after Hodgkin's lymphoma therapy. 27, 30, 32 
Cardiovascular Disease After Chemotherapy
In recent years, data are available on the relationship between chemotherapy for Hodgkin's lymphoma and risk of cardiac complications. Aviles et al 26 
A British study also demonstrated the independent effect of chemotherapy on risk of cardiac mortality, although the relative risks were less dramatically elevated. This study included 7033 patients with Hodgkin's lymphoma treated from 1967 to 2000. 33 At a mean follow-up of 11.1 years, a total of 166 myocardial infarction deaths were observed. The risk of cardiac mortality was separately analyzed for patients who received chemotherapy with mediastinal irradiation and chemotherapy without mediastinal irradiation. Among patients who were treated with ABVD and mediastinal irradiation, the relative risk of cardiac mortality was significantly elevated at 12.1 (P ϭ 0.004). However, patients who received ABVD without mediastinal irradiation were also found to have a significantly elevated relative risk of cardiac mortality of 7.8 (P ϭ 0.01). The relative risks of cardiac mortality after treatment with any adriamycin-based chemotherapy with and without mediastinal irradiation were 2.4 (P ϭ 0.05) and 3.2 (P Ͻ 0.001), respectively.
Screening for Cardiovascular Disease
Because of the well-documented increased risks of cardiac complications in Hodgkin's lymphoma survivors, investigators have described the use of cardiac screening tools in asymptomatic patients. In a prospective study from Stanford University, 294 asymptomatic patients treated with mediastinal irradiation for Hodgkin's lymphoma underwent electrocardiography and echocardiography screening at a median time of 15 years from initial treatment. 23 Significant valvular abnormality, depressed left ventricular fractional shortening, regional wall motion abnormality, decreased left ventricular mass and pericardial thickening, all of which also increased with increasing time from initial irradiation. In the most recent report from the same group, the focus was on coronary disease among participants of the screening trial. 34 During stress testing, 14% developed perfusion defects, impaired wall motion, or both abnormalities. Based on the imaging results, 40 patients (14%) underwent coronary angiography. As a result of the screening, 7 of these asymptomatic patients (2.4%) underwent bypass graft surgery. In addition, 23 patients (8%) subsequently developed coronary events during a median of 6.5 years of follow-up, including10 cases of acute myocardial infarctions. Of note, the median dose to the mediastinum among patients included in this Stanford screening study was 44 Gy (range, 35-54.6 Gy), which are doses that are considerably higher than those used in current practice.
Adams et al 24 conducted a prospective cardiac screening study along with quality-of-life evaluation on 48 asymptomatic
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Late Effects After HD childhood Hodgkin's lymphoma survivors. The median age of the study population at the time of initial therapy was 16.5 years, and the median dose received was 40 Gy. The median follow time was 14.3 years. On echocardiogram, 42% were found to have significant valve defects, 75% had conduction defects, and 22% had echocardiographic changes suggestive of restrictive cardiomyopathy. A significant association between aortic regurgitation and decreased physical component score on the SF-36 was found (P ϭ 0.01). A decreased peak myocardial oxygen uptake during exercise (VO 2max ), a predictor of mortality in heart failure, was associated with increased fatigue (P ϭ 0.02) and decreased physical component score (P ϭ 0.00017). These findings suggest that the late effects of treatment can contribute to quality-of-life impairment and fatigue in long-term Hodgkin's lymphoma survivors.
OTHER LATE EFFECTS

Noncoronary Vascular Complications
Emerging data are available on the risk of noncoronary vascular disease as a late complication after Hodgkin's lymphoma therapy. Hull et al 27 reported an actuarial incidence of noncoronary atherosclerotic disease of 2% at 5 years, 3% at 10 years, and 7% at 20 years, respectively, among 415 Hodgkin's lymphoma survivors. The median dose to the low neck was significantly higher in patients who developed subclavian artery stenosis than those who did not (44 Gy and 36 Gy, respectively, P ϭ 0.002). Similarly, the median dose to the low neck was 38 Gy among patients who developed carotid artery stenosis and 36 Gy in patients who did not (P ϭ 0.05). In addition, hypertension (P ϭ 0.003) and diabetes mellitus (P ϭ 0.001) were both significant independent factors associated with noncoronary atherosclerotic disease in this population. A report from the Childhood Cancer Survivor Study examined the incidence of stroke in survivors of pediatric Hodgkin's lymphoma. 35 Compared with the siblings, there was a 5.6-fold higher risk of stroke in survivors of Hodgkin's lymphoma who received mantle radiation therapy. The median dose to the mantle field in survivors who developed a stroke was 40 Gy. Unlike the study by Hull et al, hypertension and diabetes mellitus did not significantly increase the risk of stroke, but a smoking history was a significant predictor (OR ϭ 3.37, P ϭ 0.026). Currently, the role of screening for noncoronary vascular disease in Hodgkin's lymphoma survivors is unknown. However, it is important to note that modern approaches to Hodgkin's lymphoma therapy use lower radiation doses, smaller fields, and planning techniques that limit dose inhomogeneity and hot spots commonly seen in the neck area with older techniques. It is therefore anticipated that noncoronary vascular complications will be less of a concern in more recently treated patients.
Thyroid Dysfunction
The most common thyroid abnormality after radiation therapy for Hodgkin's lymphoma is hypothyroidism. In a study by Hancock et al, 36 the actuarial risk of hypothyroidism after radiation therapy for Hodgkin's lymphoma was 47% at 26 years. Other less common thyroid abnormalities observed included Graves' disease, thyroiditis, thyrotoxicosis, thyroid nodules, and thyroid malignancies.
The risk of radiation-related thyroid dysfunction seems to be dose related. 37, 38 In a study from the University of Minnesota, the estimated actuarial risk of developing hypothyroidism was 60% at 11 years. 39 In addition, the relative risk of hypothyroidism was estimated to increase by 1.02/Gy. Patients who have received radiation therapy to the neck region for Hodgkin's lymphoma would therefore benefit from thyroid function testing as part of follow-up.
Sterility
Radiation therapy can induce germinal epithelium depletion in a dose-related manner. 40 -43 Decrease in sperm count can be observed after doses as low as 0.15 Gy. A 1-time dose of 0.35 Gy or higher can cause transient azoospermia. The recovery time increases with increasing dose, and doses of 2 Gy or higher to the germinal epithelium can result in permanent azoospermia. At doses of 15 Gy or higher, Leydig cell function can be affected, with potential need for testosterone replacement therapy. In men who are receiving pelvic radiation therapy for Hodgkin's lymphoma, cryopreservation of semen before intiation of therapy should be strongly considered. Adequate testicular shielding can also reduce the risk of permanent azoospermia.
The effect of chemotherapy for Hodgkin's lymphoma on male reproductive function had also been extensively explored. After 6 to 8 cycles of MOPP chemotherapy, 80% to 90% of patients will develop azoospermia. 44 In a recent cohort study conducted by the EORTC, exposure to alkylating chemotherapy was associated with a significantly higher risk of gonadal dysfunction among male patients and longer recovery time of gonadal function. 45 The current standard systemic therapy for Hodgkin's lymphoma, ABVD, can lead to transient azoospermia in about one third of patients, but the majority of patients will have recovery of spermatogenesis after treatment. 44, 46 However, the BEACOPP regimen, developed by the German Hodgkin's Study Group for patients with advanced-stage or unfavorable Hodgkin's lymphoma, 9 is associated with an increased risk of sterility. In a recent study on 38 male patients treated with BEACOPP, at baseline, 77% patients had dysspermia. After treatment, 89% patients had azoospermia, 11% had other dysspermia, and no patients had normozoospermia. 47 Ionizing radiation can cause direct DNA damage to ovarian follicles, leading to follicular atrophy and decreased follicular reserve within the ovary. An ovarian dose of 4 Gy may cause a 30% incidence of sterility in young women but 100% sterility in women over 40 years of age. 43 In women receiving pelvic irradiation for Hodgkin's lymphoma, oophoropexy, which can be achieved laparscopically can reduce the dose delivered to the ovaries and preserve fertility. 48, 49 The effect of chemotherapy on female reproductive function was explored in a cohort study of 518 female survivors of Hodgkin's lymphoma. 50 At a median follow-up of 9.4 years, chemotherapy was associated with a 12.3-fold increased risk of premature menopause compared with radiotherapy alone. A significant dose-response relationship was demonstrated with exposures to alkylating chemotherapy, most notably for procarbazine and cyclophosphamide. In a case-control survey study of female Hodgkin's lymphoma survivors treated with ABVD, no significant subfertility was found. 51 However, the BEACOPP regimen can result in continues amenorrhea in over 50% of women. 14 
SUMMARY
In view of the increased risk for various late effects after treatment for Hodgkin's lymphoma, patient education regarding the risks, and promoting healthy behavior to reduce modifiable risk factors (eg, sun safety practice, smoking cessation, dietary changes, and weight control) are essential. In addition, early-detection and prevention strategies, especially for the more serious, potentially life-threatening late effects including second malignancies and cardiac disease, should be considered in high-risk patients. These include mammography and breast magnetic resonance imaging screening in women who had received chest irradiation at a young age, and low-dose chest computed tomography screening in survivors with a smoking history and who have received chest irradiation and/or alkylating chemotherapy. Survivors with history of exposures to adriamycin-based chemotherapy or mediastinal irradiation may also benefit from cardiac screening tests, and routine blood pressure and lipid screening. However, the efficacy of these tests, and their optimal timing and frequency, remain to be determined.
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It is important to note that most of the documented late effects after Hodgkin's lymphoma therapy are based on patients treated with outdated chemotherapy and radiation fields, doses, and techniques. Modeling data have shown that treatment with limited radiation fields to lower doses can significantly reduce second malignancy risk. 52 Current efforts of additional reduction in radiation field sizes and doses will likely further reduce late complications. 25, 53, 54 Recent advances in conformal radiation therapy techniques can also effectively limit doses critical normal structures. 55, 56 As Hodgkin's lymphoma therapy evolves, it is imperative to continue the long-term follow-up of survivors with careful documentation of late effects associated with new treatments. Understanding the contribution of other modifying factors in the context of modern therapy, including genetic factors, environmental factors, and lifestyle choices may further help guide patient counseling and refine follow-up recommendations.
